Analyst Price Targets — DSGN
Latest News for DSGN
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong
CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present at the following upcoming investor conferences: Oppenheimer 36 th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026, at 1:20 p.m.
Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $10.13, but opened at $10.48. Design Therapeutics shares last traded at $10.10, with a volume of 9,741 shares changing hands. Analyst Ratings Changes DSGN has been the topic of several analyst
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DSGN.
U.S. House Trading
No House trades found for DSGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.